Guidelines for monitoring drug therapy in rheumatoid arthritis
Open Access
- 1 May 1996
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 39 (5), 723-731
- https://doi.org/10.1002/art.1780390503
Abstract
No abstract availableThis publication has 51 references indexed in Scilit:
- The total costs of drug therapy for rheumatoid arthritisArthritis & Rheumatism, 1995
- Are There Differences Among Nonsteroidal Antiinflammatory Drugs?Arthritis & Rheumatism, 1994
- Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapyArthritis & Rheumatism, 1989
- Histocompatibility antigens in systemic‐onset juvenile rheumatoid arthritisArthritis & Rheumatism, 1989
- Ocular effects and safety of antimalarial agentsAmerican Journal Of Medicine, 1988
- Clinical spectrum of the upper gastrointestinal effects of nonsteroidal anti-inflammatory drugs: Natural history, symptomatology, and significanceAmerican Journal Of Medicine, 1988
- Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years.BMJ, 1986
- ANTIRHEUMATIC MEDICATION DURING LACTATIONRheumatology, 1985
- Renal Syndromes Associated with Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1984
- Incidence of sulphasalazine-induced male infertility.Gut, 1981